[go: up one dir, main page]

JP2004514660A - Ｈｓｐ９０に結合するための小分子組成物 - Google Patents

Ｈｓｐ９０に結合するための小分子組成物 Download PDF

Info

Publication number
JP2004514660A
JP2004514660A JP2002538887A JP2002538887A JP2004514660A JP 2004514660 A JP2004514660 A JP 2004514660A JP 2002538887 A JP2002538887 A JP 2002538887A JP 2002538887 A JP2002538887 A JP 2002538887A JP 2004514660 A JP2004514660 A JP 2004514660A
Authority
JP
Japan
Prior art keywords
hsp90
binding
small molecule
molecule compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002538887A
Other languages
English (en)
Other versions
JP2004514660A6 (ja
JP4406205B2 (ja
Inventor
チオシス，ガブリエラ
ローゼン，ニール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of JP2004514660A publication Critical patent/JP2004514660A/ja
Publication of JP2004514660A6 publication Critical patent/JP2004514660A6/ja
Application granted granted Critical
Publication of JP4406205B2 publication Critical patent/JP4406205B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

なし。

Description

なし。

Claims (1)

  1. なし。
JP2002538887A 2000-11-02 2001-11-01 Ｈｓｐ９０に結合するための小分子組成物 Expired - Fee Related JP4406205B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24517700P 2000-11-02 2000-11-02
PCT/US2001/046303 WO2002036075A2 (en) 2000-11-02 2001-11-01 Small molecule compositions for binding to hsp90

Publications (3)

Publication Number Publication Date
JP2004514660A true JP2004514660A (ja) 2004-05-20
JP2004514660A6 JP2004514660A6 (ja) 2004-08-19
JP4406205B2 JP4406205B2 (ja) 2010-01-27

Family

ID=22925604

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002538887D Pending JP2005519848A (ja) 2000-11-02 2001-11-01 Ｈｓｐ９０に結合するための小分子組成物
JP2002538887A Expired - Fee Related JP4406205B2 (ja) 2000-11-02 2001-11-01 Ｈｓｐ９０に結合するための小分子組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002538887D Pending JP2005519848A (ja) 2000-11-02 2001-11-01 Ｈｓｐ９０に結合するための小分子組成物

Country Status (8)

Country Link
US (1) US7439359B2 (ja)
EP (1) EP1335920B1 (ja)
JP (2) JP2005519848A (ja)
KR (1) KR100850727B1 (ja)
CN (2) CN1501928A (ja)
AU (2) AU2877102A (ja)
CA (1) CA2426952C (ja)
WO (1) WO2002036075A2 (ja)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
EP1423080A4 (en) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS
EP1551957A4 (en) * 2001-10-01 2007-01-24 Univ Duke ISOLATED POLYPEPTIDE OF THE GRP94 LIGANDEN BINDING DOMAIN AND NUCLEIC ACID, CRYSTALLINE FORM THEREOF, CODING THEREOF, AND SCRAPPING METHOD WHERE IT IS USED
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
CA2474508A1 (en) 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
EP1572933A4 (en) * 2002-02-13 2007-09-05 Univ Duke MODULATION OF THE IMMUNE RESPONSE BY POLYPEPTIDES AS AN ANSWER TO NONPEPTIDIC BINDING STRENGTH
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
WO2004069999A2 (ja) * 2003-02-04 2004-08-19 Takeda Pharmaceutical Company Limited スクリーニング方法
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
GB0309637D0 (en) * 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
CA2530374C (en) 2003-06-27 2012-05-15 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
WO2006052795A2 (en) * 2004-11-05 2006-05-18 University Of Rochester Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0501535D0 (en) * 2005-01-25 2005-03-02 Vernalis R&D Ltd Pyrimidothiophene compounds
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
CN101160291B (zh) 2005-03-09 2012-09-05 日本化药株式会社 作为hsp90抑制剂的三唑衍生物
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
JP2008534609A (ja) * 2005-03-30 2008-08-28 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体
EA200702235A1 (ru) * 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2049497A2 (en) * 2005-05-19 2009-04-22 Astex Therapeutics Limited Pyrimidine derivatives as hsp90 inhibitors
WO2006130469A1 (en) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
EP1904452A2 (en) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
EP1962863A4 (en) * 2005-12-22 2010-11-24 Conforma Therapeutics Corp ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90
AU2007249194B2 (en) 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
DK2034839T3 (en) * 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
US8067412B2 (en) * 2006-08-11 2011-11-29 Universite De Strasbourg Macrocyclic compounds useful as inhibitors of kinases and HSP90
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
KR20090104920A (ko) 2007-02-01 2009-10-06 아스트라제네카 아베 Ｈｓｐ90 억제제로서 5,6,7,8-테트라히드로프테리딘 유도체
PE20090110A1 (es) 2007-03-01 2009-04-04 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
TW200901960A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
ES2430217T3 (es) * 2007-03-20 2013-11-19 Curis, Inc. Aminopiridina condensada como inhibidores de HSP90
AU2008240153B2 (en) 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
GB0718255D0 (en) * 2007-09-19 2007-10-31 Univ Edinburgh Nucleobase characterisation
EP2219448A4 (en) * 2007-11-14 2011-10-12 Myriad Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
US7960420B2 (en) 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
US8895701B2 (en) * 2008-01-05 2014-11-25 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
SG187502A1 (en) * 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
WO2009134938A1 (en) 2008-04-29 2009-11-05 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2009143485A1 (en) 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤
EP2387316A4 (en) * 2009-01-16 2012-06-13 Curis Inc CONDENSED AMINOPYRIDINE FOR THE TREATMENT OF BRAIN TUMORS
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US20120283120A1 (en) 2009-09-29 2012-11-08 Takeda Pharmaceutical Company Limited Screening method
AU2010303343B2 (en) 2009-10-07 2015-11-19 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as HSP90 inhibitors
AU2011272860A1 (en) 2010-06-30 2013-02-07 Brandeis University Small-molecule-targeted protein degradation
WO2012116145A1 (en) * 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
HRP20171930T1 (hr) 2011-04-22 2018-02-09 Joyant Pharmaceuticals, Inc. Analozi diazonamida
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
KR102240571B1 (ko) * 2013-06-27 2021-04-15 칭화 유니버시티 종양 바이오마커
CA2921571C (en) * 2013-08-16 2022-04-05 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
CN105147693B (zh) * 2015-09-23 2018-01-12 昆明理工大学 一种小分子化合物在制备抗肺癌药物中的应用
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
MA53668B1 (fr) 2018-09-19 2024-06-28 Novo Nordisk Health Care Ag Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
MA57202B1 (fr) 2019-09-19 2025-09-30 Novo Nordisk Health Care Ag Compositions d'activation de la pyruvate kinase r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2729642A (en) * 1954-08-13 1956-01-03 Chattanooga Medicine Co Water soluble salts of 8-(para-aminobenzyl) caffeine and method for their preparation
US3930005A (en) * 1973-06-15 1975-12-30 Squibb & Sons Inc Antiinflammatory agents and their use
US4172829A (en) * 1978-05-09 1979-10-30 Bristol-Myers Company 2,9-Disubstituted adenine derivatives and their use as non-adrenergic bronchodilators
EP0193454A1 (en) * 1985-02-25 1986-09-03 Merck & Co. Inc. 8-Substituted-9-hydroxyalkyl and hydroxyalkoxymethyl-guanines and pharmaceutical compositions containing them
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
EP0363320A3 (de) * 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
DE4216846A1 (de) * 1992-05-21 1993-11-25 Basf Ag Verfahren zur Fixierung großer zeolithischer und zeolithanaloger Molekularsieb-Kristalle auf Formkörper
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
CZ99797A3 (en) * 1994-10-05 1997-09-17 Chiroscience Ltd Purine and guanine compounds as pnp inhibitors
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6294541B1 (en) * 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
KR20020065341A (ko) 1999-04-02 2002-08-13 유로-셀티크 소시에떼 아노뉨 포스포디에스트라스(phosphodiesterase, PDE) Ⅳ 억제작용을 가진 푸린 유도체
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
US6335157B1 (en) * 1999-05-07 2002-01-01 The European Molecular Biology Laboratory Method based on localization of Hsp90 to the centrosome
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
US6946456B2 (en) * 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US7138401B2 (en) * 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity

Also Published As

Publication number Publication date
KR20030071767A (ko) 2003-09-06
CN101928288A (zh) 2010-12-29
EP1335920B1 (en) 2013-04-03
WO2002036075A3 (en) 2003-06-05
KR100850727B1 (ko) 2008-08-06
EP1335920A4 (en) 2005-08-17
CA2426952A1 (en) 2002-05-10
US7439359B2 (en) 2008-10-21
AU2877102A (en) 2002-05-15
CN101928288B (zh) 2013-09-11
AU2002228771B2 (en) 2007-10-25
WO2002036075A2 (en) 2002-05-10
JP4406205B2 (ja) 2010-01-27
JP2005519848A (ja) 2005-07-07
CA2426952C (en) 2012-06-26
CN1501928A (zh) 2004-06-02
US20040102458A1 (en) 2004-05-27
EP1335920A2 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
JP2004514660A (ja) Ｈｓｐ９０に結合するための小分子組成物
IT1308627B1 (it) Composizioni fluoroelastomeriche.
MA26948A1 (fr) Guanidinobenzamides comme mc4-r agonistes.
IT1308628B1 (it) Composizioni fluoroelastomeriche.
RU2002121642A (ru) Гербицидная композиция
ATE387438T1 (de) Neue 1,2,4-triazolverbindung
ATE303787T1 (de) Schergelzusammensetzungen
AR028197A1 (es) Composiciones antitranspirantes
ATE314049T1 (de) Schweisshemmende zusammensetzungen
DE60131960D1 (de) Fungizide zusammensetzungen, die n-(alpha-cyano-2-thenyl)-4-ethyl-2-ethylamino-5-thiazolcarboxamide enthalten
AR028248A1 (es) Nuevos compuestos 2,3,4,5-tetrahidro-1h-(1,4) diazepino (1,7-a) indol
MXPA03001802A (es) Composicion acondicionadora pre-champu.
DE50109142D1 (de) Builder-Zusammensetzung
JP2003284553A5 (ja)
ITTO20020744A1 (it) Composizione.
RU2000118409A (ru) Антимутагенное средство
BR0112787B1 (pt) composiÇço de soluÇço topicamente administrÁvel.
IT1317827B1 (it) Composizioni solventi.
ITTO20020745A1 (it) Composizione.
RU2000116332A (ru) Антгельминтное средство
RU2000115217A (ru) Средство для лечения хронического эндометрита
IT1319677B1 (it) Composizione funghicida.
JP2002183991A5 (ja)
ITMI990856A1 (it) Composizione funghicida.
ITTO20020746A1 (it) Composizione.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091020

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091106

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121113

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121113

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131113

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees